» Articles » PMID: 26351625

Quercetin Reduces Ehrlich Tumor-induced Cancer Pain in Mice

Abstract

Cancer pain directly affects the patient's quality of life. We have previously demonstrated that the subcutaneous administration of the mammary adenocarcinoma known as Ehrlich tumor induces pain in mice. Several studies have shown that the flavonoid quercetin presents important biological effects, including anti-inflammatory, antioxidant, analgesic, and antitumor activity. Therefore, the analgesic effect and mechanisms of quercetin were evaluated in Ehrlich tumor-induced cancer pain in mice. Intraperitoneal (i.p.) treatments with quercetin reduced Ehrlich tumor-induced mechanical and thermal hyperalgesia, but not paw thickness or histological alterations, indicating an analgesic effect without affecting tumor growth. Regarding the analgesic mechanisms of quercetin, it inhibited the production of hyperalgesic cytokines IL-1β and TNFα and decreased neutrophil recruitment (myeloperoxidase activity) and oxidative stress. Naloxone (opioid receptor antagonist) inhibited quercetin analgesia without interfering with neutrophil recruitment, cytokine production, and oxidative stress. Importantly, cotreatment with morphine and quercetin at doses that were ineffective as single treatment reduced the nociceptive responses. Concluding, quercetin reduces the Ehrlich tumor-induced cancer pain by reducing the production of hyperalgesic cytokines, neutrophil recruitment, and oxidative stress as well as by activating an opioid-dependent analgesic pathway and potentiation of morphine analgesia. Thus, quercetin treatment seems a suitable therapeutic approach for cancer pain that merits further investigation.

Citing Articles

Leaves Extracts Inhibit the Development of Ascitic and Solid Ehrlich Tumors.

Silva L, Cavallini E, da Silva R, SantAna M, Yoshikawa A, Salomao T Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861087 PMC: 11768557. DOI: 10.3390/ph18010024.


Proteostasis Decline and Redox Imbalance in Age-Related Diseases: The Therapeutic Potential of NRF2.

Buttari B, Tramutola A, Rojo A, Chondrogianni N, Saha S, Berry A Biomolecules. 2025; 15(1).

PMID: 39858508 PMC: 11764413. DOI: 10.3390/biom15010113.


From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design.

Turnaturi R, Piana S, Spoto S, Costanzo G, Reina L, Pasquinucci L Molecules. 2024; 29(4).

PMID: 38398566 PMC: 10892999. DOI: 10.3390/molecules29040815.


Targeting Oxidative Stress, Autophagy, and Apoptosis by Quercetin to Ameliorate Cisplatin-induced Peripheral Neuropathy in Rats.

Mahmoud H, Horany H, Aboalsoud M, Abd-Ellatif R, Sheikh A, Aboalsoud A J Microsc Ultrastruct. 2023; 11(2):107-114.

PMID: 37448816 PMC: 10337675. DOI: 10.4103/jmau.jmau_78_22.


Recent Advances in Biologically Active Ingredients from Natural Drugs for Sepsis Treatment.

Zheng Z, Song X, Shi Y, Long X, Li J, Zhang M Comb Chem High Throughput Screen. 2023; 27(5):688-700.

PMID: 37254548 DOI: 10.2174/1386207326666230529101918.


References
1.
Constantin C, Mair N, Sailer C, Andratsch M, Xu Z, Blumer M . Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci. 2008; 28(19):5072-81. PMC: 6670746. DOI: 10.1523/JNEUROSCI.4476-07.2008. View

2.
Valko M, Leibfritz D, Moncol J, Cronin M, Mazur M, Telser J . Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2006; 39(1):44-84. DOI: 10.1016/j.biocel.2006.07.001. View

3.
Fernandes P, Guerra F, Sales N, Sardella T, Jancar S, Neves J . Characterization of the inflammatory response during Ehrlich ascitic tumor development. J Pharmacol Toxicol Methods. 2014; 71:83-9. DOI: 10.1016/j.vascn.2014.09.001. View

4.
Naidu P, Singh A, Joshi D, Kulkarni S . Possible mechanisms of action in quercetin reversal of morphine tolerance and dependence. Addict Biol. 2003; 8(3):327-36. DOI: 10.1080/13556210310001602248. View

5.
Zhang R, Liu Y, Zhang J, Zheng Y, Gu X, Ma Z . Intrathecal administration of roscovitine attenuates cancer pain and inhibits the expression of NMDA receptor 2B subunit mRNA. Pharmacol Biochem Behav. 2012; 102(1):139-45. DOI: 10.1016/j.pbb.2012.03.025. View